BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar M, Abbas Z, Azami M, Belopolskaya M, Dokmeci AK, Ghazinyan H, Jia J, Jindal A, Lee HC, Lei W, Lim SG, Liu CJ, Li Q, Al Mahtab M, Muljono DH, Niriella MA, Omata M, Payawal DA, Sarin SK, Ségéral O, Tanwandee T, Trehanpati N, Visvanathan K, Yang JM, Yuen MF, Zheng Y, Zhou YH. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. Hepatol Int 2022. [PMID: 35113359 DOI: 10.1007/s12072-021-10285-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Parveen S, Tiwari A, Singh J, Shah A. HBV in pregnancy: time to consider tenofovir alafenamide (TAF). Hepatol Int. [DOI: 10.1007/s12072-022-10382-z] [Reference Citation Analysis]
2 Luo Y, Xiang K, Liu J, Song J, Feng J, Chen J, Dai Y, Hu Y, Zhuang H, Zhou Y. Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients 2022;14:1561. [DOI: 10.3390/nu14081561] [Reference Citation Analysis]
3 Kumar M. Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed. Hepatol Int 2022. [PMID: 35794305 DOI: 10.1007/s12072-022-10376-x] [Reference Citation Analysis]